Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials.
The Lancet Oncology.
Times cited: 71
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.
Cancer Chemotherapy and Pharmacology.
Times cited: 17